

Subject: Medical Science Liaison (MSL) Notes - Skepticism and Concerns on NanoFlexa

Date: July 28, 2025

Provider: Dr. Jonathan Turner

Title: Rheumatologist

Institution: JointEase Rheumatology Clinic

Summary of Key Discussion Points:

1. Introduction:

- Introduced NanoFlexa as an innovative therapy for rheumatoid arthritis with a nanoparticle-based delivery system.
- Dr. Turner expressed skepticism, questioning the need for a localized delivery system for RA treatment.

2. Provider's Current Patient Cases:

- Dr. Turner shared reservations about introducing a new delivery method without clear advantages over existing systemic therapies.
- Discussed specific cases where traditional DMARDs and biologics have shown established efficacy in managing RA.

3. Efficacy and Clinical Data:

- Presented recent clinical data showcasing NanoFlexa's reduction in RA disease activity scores and improvements in joint function.
- Dr. Turner questioned the clinical significance of the reported improvements and sought comparative data against established treatments.

4. Safety Profile:

- Discussed the favorable safety profile of NanoFlexa, with the unique benefit of localized joint delivery.
- Dr. Turner expressed concerns about potential unknowns with localized delivery and questioned the long-term safety implications.

5. Mechanism of Action:

- Explained NanoFlexa's mode of delivery, utilizing a subcutaneous implant with controlled release of nanoparticles at the joint site.
- Dr. Turner questioned the necessity for such a novel delivery method and expressed concerns about patient acceptance.

6. Patient Adherence and Education:

- Discussed strategies for enhancing patient adherence through the convenience of a semi-annual subcutaneous implant.

- Dr. Turner expressed skepticism about patient compliance, citing potential apprehensions and discomfort with the implant procedure.

7. Emerging Research and Future Developments:

- Highlighted ongoing research on NanoFlexa's potential in other inflammatory joint conditions.
- Dr. Turner questioned the need for expanding research without addressing existing concerns about the drug's efficacy and delivery.

8. Competitive Landscape:

- Compared NanoFlexa to existing systemic DMARDs, expressing doubts about its potential advantages.
- Discussed challenges of introducing a new drug and delivery method without clear benefits over established treatments.

9. Access and Reimbursement:

- Provided updates on access and reimbursement programs for rheumatology clinics.
- Dr. Turner expressed reservations about the cost-effectiveness of NanoFlexa compared to existing treatments.

10. Action Items and Follow-Up:

- Dr. Turner declined any further collaboration or follow-up in the near future.
- Expressed a preference for waiting until more substantial data and real-world evidence on NanoFlexa's efficacy and safety become available.

11. Closing Remarks:

- Acknowledged Dr. Turner's concerns and thanked him for his candid feedback.
- Expressed understanding and commitment to addressing ongoing questions or concerns if additional data becomes available.